These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 19241459)

  • 41. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease.
    Abramowicz A; Gos M
    Dev Period Med; 2014; 18(3):297-306. PubMed ID: 25182393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of NF1 gene mutations in neurofibromatosis type 1 patients in Japan.
    Hatta N; Horiuchi T; Fujita S
    Biochem Biophys Res Commun; 1994 Feb; 199(1):207-12. PubMed ID: 8123014
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A de novo Alu insertion results in neurofibromatosis type 1.
    Wallace MR; Andersen LB; Saulino AM; Gregory PE; Glover TW; Collins FS
    Nature; 1991 Oct; 353(6347):864-6. PubMed ID: 1719426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neurofibromatosis type 1 gene mutations in neuroblastoma.
    The I; Murthy AE; Hannigan GE; Jacoby LB; Menon AG; Gusella JF; Bernards A
    Nat Genet; 1993 Jan; 3(1):62-6. PubMed ID: 8490657
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mid-aortic syndrome with renovascular hypertension and multisystem involvement in a girl with familiar neurofibromatosis von Recklinghausen type 1.
    Petrak B; Bendova S; Seeman T; Klein T; Lisy J; Zatrapa T; Marikova T
    Neuro Endocrinol Lett; 2007 Dec; 28(6):734-8. PubMed ID: 18063929
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Characterization of the neurofibromatosis type 1 gene and neurofibromin's role in cells].
    Sakai A
    Nihon Rinsho; 2000 Jul; 58(7):1426-9. PubMed ID: 10921317
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reproductive decisions after prenatal diagnosis in neurofibromatosis type 1: importance of genetic counseling.
    Terzi YK; Oguzkan-Balci S; Anlar B; Aysun S; Guran S; Ayter S
    Genet Couns; 2009; 20(2):195-202. PubMed ID: 19650418
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors.
    Kluwe L; Friedrich RE; Peiper M; Friedman J; Mautner VF
    Hum Mutat; 2003 Nov; 22(5):420. PubMed ID: 14517963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of NF1 mutations in both alleles of a dermal neurofibroma.
    Sawada S; Florell S; Purandare SM; Ota M; Stephens K; Viskochil D
    Nat Genet; 1996 Sep; 14(1):110-2. PubMed ID: 8782831
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype.
    Pasmant E; Sabbagh A; Spurlock G; Laurendeau I; Grillo E; Hamel MJ; Martin L; Barbarot S; Leheup B; Rodriguez D; Lacombe D; Dollfus H; Pasquier L; Isidor B; Ferkal S; Soulier J; Sanson M; Dieux-Coeslier A; Bièche I; Parfait B; Vidaud M; Wolkenstein P; Upadhyaya M; Vidaud D;
    Hum Mutat; 2010 Jun; 31(6):E1506-18. PubMed ID: 20513137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Fifty-four novel mutations in the NF1 gene and integrated analyses of the mutations that modulate splicing.
    Xu W; Yang X; Hu X; Li S
    Int J Mol Med; 2014 Jul; 34(1):53-60. PubMed ID: 24789688
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1.
    Weiss B; Bollag G; Shannon K
    Am J Med Genet; 1999 Mar; 89(1):14-22. PubMed ID: 10469432
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Using antisense oligonucleotides for the physiological modulation of the alternative splicing of NF1 exon 23a during PC12 neuronal differentiation.
    Biayna J; Mazuelas H; Gel B; Terribas E; Dumbovic G; Rosas I; Fernández-Rodriguez J; Blanco I; Castellanos E; Carrió M; Lazaro C; Serra E
    Sci Rep; 2021 Feb; 11(1):3661. PubMed ID: 33574490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders.
    Side L; Taylor B; Cayouette M; Conner E; Thompson P; Luce M; Shannon K
    N Engl J Med; 1997 Jun; 336(24):1713-20. PubMed ID: 9180088
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased neurofibromatosis 1 gene expression in astrocytic tumors: positive regulation by p21-ras.
    Gutmann DH; Giordano MJ; Mahadeo DK; Lau N; Silbergeld D; Guha A
    Oncogene; 1996 May; 12(10):2121-7. PubMed ID: 8668337
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antisense oligonucleotide therapeutics for iron-sulphur cluster deficiency myopathy.
    Kollberg G; Holme E
    Neuromuscul Disord; 2009 Dec; 19(12):833-6. PubMed ID: 19846308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of disease-associated HRPT2 mutations on splicing.
    Hahn MA; McDonnell J; Marsh DJ
    J Endocrinol; 2009 Jun; 201(3):387-96. PubMed ID: 19332451
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of CpG C-to-T mutations in neurofibromatosis type 1. Mutations in brief no. 129. Online.
    Krkljus S; Abernathy CR; Johnson JS; Williams CA; Driscoll DJ; Zori R; Stalker HJ; Rasmussen SA; Collins FS; Kousseff BG; Baumbach L; Wallace MR
    Hum Mutat; 1998; 11(5):411. PubMed ID: 10336779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Disease-causing mutations improving the branch site and polypyrimidine tract: pseudoexon activation of LINE-2 and antisense Alu lacking the poly(T)-tail.
    Meili D; Kralovicova J; Zagalak J; Bonafé L; Fiori L; Blau N; Thöny B; Vorechovsky I
    Hum Mutat; 2009 May; 30(5):823-31. PubMed ID: 19280650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.